NOW APPROVED IN
LOCALLY ADVANCED BCC

LIBTAYO is the first and ONLY treatment indicated for patients with locally
advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway
inhibitor (HHI) or for whom an HHI is not appropriate.1

LIBTAYO was studied in the largest
clinical trial for a PD-1 inhibitor
in patients with locally advanced
BCC after HHIs.1

Explore the data >

Review case studies of patients
with locally advanced BCC
from the clinical trial.

See the results >

Speak with a representative

If you would like to get more information
about LIBTAYO, you can request a visit from
a LIBTAYO field representative.

Contact a rep >
LIBTAYO Surround® logo

Learn about the LIBTAYO Surround Patient Support Program

Reference: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC.